Structure Therapeutics (NASDAQ:GPCR) Rating Reiterated by Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reiterated by research analysts at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $65.00 target price on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 47.66% from the stock’s current price.

Several other research firms have also commented on GPCR. BMO Capital Markets upped their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, June 7th. Morgan Stanley started coverage on shares of Structure Therapeutics in a research report on Monday. They issued an “overweight” rating and a $118.00 price objective for the company. Finally, JMP Securities decreased their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research report on Friday, August 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $88.33.

Structure Therapeutics Trading Up 3.9 %

NASDAQ GPCR opened at $44.02 on Monday. The firm’s fifty day simple moving average is $37.91 and its two-hundred day simple moving average is $39.71. Structure Therapeutics has a 12-month low of $26.61 and a 12-month high of $75.02. The firm has a market capitalization of $2.05 billion, a P/E ratio of -57.17 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, sell-side analysts predict that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several large investors have recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky grew its stake in Structure Therapeutics by 28.5% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock valued at $693,000 after acquiring an additional 3,918 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $1,369,000. Quarry LP purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $79,000. Driehaus Capital Management LLC grew its stake in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after acquiring an additional 86,833 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in Structure Therapeutics during the 2nd quarter valued at about $2,160,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.